Managed Healthcare Executive17h
Stelara Biosimilar Steqeyma Launches at 85% Discount
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
Center for Biosimilars18h
More Ustekinumab Biosimilars Join US Market Share Fight
Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...
Morningstar14d
SmithRx Introduces Stelara Biosimilars to Its Autoimmune Program, Helping Clients Save a Projected $14.5M in Prescription Drug Costs
representing over 95% savings compared to Stelara (90 mg)’s list price of $35,000 per fill. Employer groups that leverage the biosimilar stand to save a projected $14.5 million annually ...
Managed Healthcare Executive9d
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.
Yahoo Finance18d
Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
YESINTEK will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality ...
Business Wire13d
SmithRx Introduces Stelara Biosimilars to Its Autoimmune Program, Helping Clients Save a Projected $14.5M in Prescription Drug Costs
SmithRx, a transparent, 100% pass-through modern pharmacy benefits manager (PBM), today announced a major expansion to its Connect 360 Autoimmune Prog ...